Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

Hydralazine HCL 10mg Tablet Manufacturing and Supply

Open
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This contract involves the manufacturing and supply of Hydralazine HCL 10mg tablets, packaged in bottles containing 100 units each. The contractor is required to ensure all products meet strict regulatory compliance, including conducting stability testing to verify product quality over time. Additionally, the labeling on the bottles must comply with all applicable government standards to ensure proper usage and safety information. The contract, issued by the Department of Veterans Affairs through Nac Pharmaceuticals, is classified under the NAICS code 325412, related to pharmaceutical manufacturing. Although specific location details and points of contact are not provided, the agreement is designated as a subcontract, emphasizing collaboration with a primary contractor or agency. The focus on regulatory adherence, stability assurance, and government-compliant packaging highlights the importance of quality and safety in supplying this essential medication.

General Info

Manufacture and supply Hydralazine HCL 10mg tablets with regulatory, stability, and labeling compliance.

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Place of Performance

IL

Set-Aside

NONE

Documents

This scope was carved out of 36e79725R0060.

The full solicitation package (4 documents), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

6505--Hydralazine HCL Tablets Effective 04/08/2026 to 04/07/2027

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

Posted

subcontract

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Veterans Affairs → Nac Pharmaceuticals (36E797)
ContactsNo contacts available
OfficeN/A
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Manufacture and delivery of Hydralazine HCL 10mg tablets in 100-unit bottles with regulatory compliance, stability testing, and government-compliant labeling.

Similar Contracts

Same NAICS industry code

More opportunities from Department Of Veterans Affairs → Nac Pharmaceuticals (36E797)

Same awarding agency

NAICS: 325412
Federal
6505--Latanoprost Ophthalmic Solution (VA-27-00006027)
Solicitation # 36E79727R0039
The Department of Veterans Affairs is soliciting proposals for the procurement of Latanoprost 0.005% Ophthalmic Solution to ensure an uninterrupted supply for the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. This unrestricted commercial item procurement is structured into two groups, with one award made in the aggregate for either Group I (single bottles) or Group II (single and bulk cartons). The resulting contract will consist of a one-year base period followed by four pre-priced one-year option periods. Distribution will be managed through the VA and DoD Pharmaceutical Prime Vendor Programs, requiring the contractor to deliver supplies to designated distribution centers based on business-to-business agreements. Award will be granted based on the lowest evaluated price among proposals that meet all non-cost acceptability standards. Offerors must provide a unique 11-digit NDC number and adhere to the American Academy of Ophthalmology’s uniform color-coding system for caps and labels. Strict compliance with FDA current Good Manufacturing Practice standards is required, and offerors must certify they possess the necessary NDA, ANDA, or BLA approvals. Additionally, products must meet rigorous barcoding and serialization requirements under the Drug Supply Chain Security Act, including the use of GS-1 data matrix codes. Proposals must be submitted by November 17, 2026, and must include a 0.5% cost recovery fee embedded in the pricing.
Pharmaceutical Preparation Manufacturing

POSTED

9 days ago

DEADLINE

in 9 days
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS